Company news

Nurix Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies

October 26, 2021

Nurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignancies at the 4th Annual Targeted Protein Degradation Summit

October 25, 2021

Nurix Therapeutics to Participate in the 4th Annual Targeted Protein Degradation Summit

October 20, 2021

Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

October 13, 2021

Nurix Therapeutics Expands its Board of Directors with the Addition of Two Industry Leaders

September 29, 2021

Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

July 12, 2021

Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President, Product Development

June 20, 2021

Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease

June 1, 2021

Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors

May 31, 2021

Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress

May 20, 2021

Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

April 12, 2021

Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

April 6, 2021

Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers

March 15, 2021

Nurix Therapeutics Announces Presentation of NX-1607 Preclinical Data at AACR

March 9, 2021

Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences

March 8, 2021

Nurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

March 8, 2021

Nurix Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

March 3, 2021

Nurix Therapeutics Announces Launch of Proposed Public Offering of Common Stock

March 1, 2021

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update

February 15, 2021

Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies

January 6, 2021

Nurix Therapeutics Announces Presentation at 39th Annual J.P. Morgan Healthcare Conference

January 4, 2021

Nurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

December 6, 2020

Nurix Therapeutics to Present at Upcoming Investor Conferences

November 8, 2020

Nurix Therapeutics to Present Preclinical Data at Upcoming 5th Medicinal Chemistry & Protein Degradation Summit and 62nd ASH Annual Meeting and Exposition

November 3, 2020

Nurix Therapeutics Announces Appointment of Robert Tjian as Chairman of Scientific Advisory Board and His Resignation from the Board of Directors

October 25, 2020

Nurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update

October 13, 2020

Nurix Therapeutics to Present at 3rd Annual Targeted Protein Degradation Summit

October 5, 2020

Nurix Therapeutics Announces Pricing of $209 Million Initial Public Offering

July 22, 2020

← Newer news releases

Decks

The 5 newest of 32 decks. Every deck is listed under its year.